Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Zacks Research reduced their Q4 2024 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research note issued on Wednesday, November 27th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $0.46 per share for the quarter, down from their prior estimate of $0.48. The consensus estimate for Catalyst Pharmaceuticals' current full-year earnings is $1.88 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals' Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.57 EPS, Q2 2026 earnings at $0.58 EPS and FY2026 earnings at $2.36 EPS.
Several other research firms have also recently issued reports on CPRX. Citigroup lifted their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an "overweight" rating and a $35.00 price objective for the company. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, August 9th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Finally, Truist Financial increased their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $31.14.
View Our Latest Report on Catalyst Pharmaceuticals
Shares of Catalyst Pharmaceuticals stock opened at $22.07 on Monday. Catalyst Pharmaceuticals has a 52-week low of $13.00 and a 52-week high of $24.27. The company has a market capitalization of $2.63 billion, a P/E ratio of 18.70, a P/E/G ratio of 3.40 and a beta of 0.75. The company has a 50 day moving average of $21.26 and a 200 day moving average of $18.79.
A number of hedge funds and other institutional investors have recently bought and sold shares of CPRX. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $258,000. Integral Health Asset Management LLC purchased a new position in Catalyst Pharmaceuticals during the second quarter worth about $4,260,000. GSA Capital Partners LLP acquired a new stake in Catalyst Pharmaceuticals in the third quarter valued at about $625,000. Capstone Investment Advisors LLC purchased a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $708,000. Finally, Allspring Global Investments Holdings LLC increased its position in Catalyst Pharmaceuticals by 146.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company's stock worth $7,285,000 after purchasing an additional 217,956 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.
In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares of the company's stock, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Molly Harper sold 17,500 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company's stock.
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.